Type 1 diabetics continue to be at risk for kidney disease
BOSTON — Advances in kidney care have not led to successful efforts to improve therapy for patients with Type 1 diabetes, according to a study published in the Journal of the American Society of Nephrology.
The study, conducted by researchers at the Joslin Diabetes Center and Brigham and Women’s Hospital, examined 423 patients with Type 1 diabetes who developed macroalbuminuria, a condition in which excess protein is passed through the urine. Patients with Type 1 diabetes have an increased risk of developing macroalbuminuria, which can lead to end-stage renal disease, also known as kidney failure. The researchers found that 172 patients developed ESRD.
Still, despite increases in the use of kidney treatments over the last 20 years, the risk of ESRD and pre-ESRD did not change, with ESRD mortality rates remaining similar between the 1990s and the 2000s.
No comments found
Hal Rosenbluth to exit Walgreens
DEERFIELD, Ill. — Walgreens on Friday announced that Hal Rosenbluth will retire as president of its health-and-wellness division in April but will continue with the company as a senior consultant to the CEO for healthcare services.
Rosenbluth was a co-founder of Take Care Health Systems, which was acquired by Walgreens in 2007. Prior to that, he led Rosenbluth International, a global travel management company, which he sold to American Express in 2003.
“Hal’s entrepreneurial spirit was instrumental to Walgreens as we expanded our pharmacy, health and wellness services through our Take Care retail clinics and worksite health centers,” stated Walgreens president and CEO Greg Wasson. “He helped these businesses become key components of Walgreens’ broad set of health-and-wellness offerings. Under Hal’s leadership, we have successfully restructured our sales and client services organization and have added to our clinical capabilities.”
“As patients increasingly become shoppers of health care, continuing to grow our services through our Take Care retail clinics and worksite health centers headquartered in Conshohocken, Pa., is central to executing our strategy of improving access and convenience in meeting the everyday needs of our patients and customers,” Wasson added.
As part of Walgreens’ community-based health solutions, the Take Care retail clinics and worksite health centers, led by Peter Hotz, now will report to Mark Wagner, president of the company’s community management division. The sales and client services organization, led by chief client officer Joe Terrion, and clinical services, led by chief medical officer Cheryl Pegus, will become part of the Walgreens pharmacy, health-and-wellness services and solutions division, under Kermit Crawford, president of the division.
No comments found
PhRMA: More than 400 rare disease treatments in development, pending approval
WASHINGTON — More than 400 drugs are in late-stage clinical development or awaiting Food and Drug Administration approval as treatments for rare diseases, according to a report by the drug industry lobby.
The Pharmaceutical Research and Manufacturers of America said a record 460 drugs were in late stages of the pipeline in a report timed to coincide with Rare Disease Day on Feb. 28. The rare or “orphan” diseases — defined by the government as those that affect fewer than 200,000 Americans — range from autoimmune disorders to cancer to blood disorders to genetic diseases. In total, there are 7,000 known rare diseases, about half of which affect children, and 80% of rare diseases affect fewer than 6,000 patients.
“Once you’ve talked to a desperate parent whose child is suffering or dying, you will be forever convinced of the need for medical innovation, including for terrible diseases that afflict even just a few,” PhRMA president and CEO John Castellani said. “Researchers at biopharmaceutical companies are working every day to bring hope to patients with limited options.”
Just a shout out to NORD ,Global Genes, Genetic Alliance and all of the wonderful organizations that are fighting for these treatments and for helping get more attention to Rare Diseases. As a Rare Mom, its a full time job finding the name of the disease, educating the medical community about it, and then getting the government to help us. This is an incredible community of intelligent, brave people.Great job moving the needle.